Gastro hep advances最新文献

{"title":"A Nonrandomized Pilot Study to Investigate the Acceptability and Feasibility of LivR Well: A Multifaceted 28-Day Home-Based Liver Optimization Program for Acute-on-Chronic Liver Failure","authors":"Natalie L.Y. Ngu ,&nbsp;Edward Saxby ,&nbsp;Thomas Worland ,&nbsp;Patricia Anderson ,&nbsp;Lisa Stothers ,&nbsp;Jo Hunter ,&nbsp;Alexander T. Elford ,&nbsp;Phil Ha ,&nbsp;Imogen Hartley ,&nbsp;Andrew Roberts ,&nbsp;Dean Seah ,&nbsp;George Tambakis ,&nbsp;Declan Connoley ,&nbsp;Anita Figredo ,&nbsp;Dilip Ratnam ,&nbsp;Danny Liew ,&nbsp;Benjamin Rogers ,&nbsp;William Sievert ,&nbsp;Sally Bell ,&nbsp;Suong Le","doi":"10.1016/j.gastha.2024.10.007","DOIUrl":"10.1016/j.gastha.2024.10.007","url":null,"abstract":"<div><h3>Background and Aims</h3><div>Acute-on-chronic liver failure (ACLF) has a 22%–74% 28-day mortality rate and 30%–40% 30-day readmission rate. We investigated the acceptability and feasibility of a multimodal community intervention for ACLF.</div></div><div><h3>Methods</h3><div>A single-arm nonrandomized pilot study of consecutive participants with ACLF was conducted in a tertiary health service. Participants received weekly medical and nursing reviews, dietetics, physiotherapy, pharmacy, social work, addiction medicine, and neuropsychiatry, where indicated. A digital platform included remote weight monitoring and online surveys. The primary outcome was acceptability/feasibility. Secondary outcomes included safety, mortality, readmission, liver disease severity, and costs.</div></div><div><h3>Results</h3><div>Fifty-nine patients were enrolled with median age 51 years (interquartile range (IQR): 45–59); majority alcohol etiology (74%),and median Model for End-Stage Liver Disease Sodium score 16 (IQR: 12–21). LivR Well was acceptable with low attrition (8 of 59), adherence to the program including home visits (mean 8.4 ± 4.2) and consultations (mean 2.4 ± 1.5) per patient. This was supported by positive feedback and themes identified through a qualitative subanalysis. Feasibility was demonstrated by recruitment rate of 4.94 patients/month and 86% completion. Mortality was lower than expected at 3%, 30-day readmission rate was 15%, and median Model for End-Stage Liver Disease Sodium score reduced to 15 (<em>P</em> = .01). Median 6-month costs reduced from $30,454 (IQR: $21,953–$65,657) to $17,657 ($4249–$42,876) (<em>P</em> = .009). The total 6-month health-care cost was $1,868,859 (95% confidence interval 1,081,821–2,655,897) compared to $2,518,227 (95% confidence interval 1,959,610–3,076,844).</div></div><div><h3>Conclusion</h3><div>LivR Well was acceptable, feasible, and safe with low short-term mortality and readmission rates. Health-care costs were reduced by 26% driven by a 40% reduction in 30-day readmission. Further evaluation includes a randomized controlled trial of LivR Well compared to standard care.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 2","pages":"Article 100567"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773469/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Large Language Models Outperform Traditional Natural Language Processing Methods in Extracting Patient-Reported Outcomes in Inflammatory Bowel Disease","authors":"Perseus V. Patel ,&nbsp;Conner Davis ,&nbsp;Amariel Ralbovsky ,&nbsp;Daniel Tinoco ,&nbsp;Christopher Y.K. Williams ,&nbsp;Shadera Slatter ,&nbsp;Behzad Naderalvojoud ,&nbsp;Michael J. Rosen ,&nbsp;Tina Hernandez-Boussard ,&nbsp;Vivek Rudrapatna","doi":"10.1016/j.gastha.2024.10.003","DOIUrl":"10.1016/j.gastha.2024.10.003","url":null,"abstract":"<div><h3>Background and Aims</h3><div>Patient-reported outcomes (PROs) are vital in assessing disease activity and treatment outcomes in inflammatory bowel disease (IBD). However, manual extraction of these PROs from the free-text of clinical notes is burdensome. We aimed to improve data curation from free-text information in the electronic health record, making it more available for research and quality improvement. This study aimed to compare traditional natural language processing (tNLP) and large language models (LLMs) in extracting 3 IBD PROs (abdominal pain, diarrhea, fecal blood) from clinical notes across 2 institutions.</div></div><div><h3>Methods</h3><div>Clinic notes were annotated for each PRO using preset protocols. Models were developed and internally tested at the University of California, San Francisco, and then externally validated at Stanford University. We compared tNLP and LLM-based models on accuracy, sensitivity, specificity, positive, and negative predictive value. In addition, we conducted fairness and error assessments.</div></div><div><h3>Results</h3><div>Interrater reliability between annotators was &gt;90%. On the University of California, San Francisco test set (n = 50), the top-performing tNLP models showcased accuracies of 92% (abdominal pain), 82% (diarrhea) and 80% (fecal blood), comparable to GPT-4, which was 96%, 88%, and 90% accurate, respectively. On external validation at Stanford (n = 250), tNLP models failed to generalize (61%–62% accuracy) while GPT-4 maintained accuracies &gt;90%. Pathways Language Model-2 and Generative Pre-trained Transformer-4 showed similar performance. No biases were detected based on demographics or diagnosis.</div></div><div><h3>Conclusion</h3><div>LLMs are accurate and generalizable methods for extracting PROs. They maintain excellent accuracy across institutions, despite heterogeneity in note templates and authors. Widespread adoption of such tools has the potential to enhance IBD research and patient care.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 2","pages":"Article 100563"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11772946/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma Circulating Metabolites Associated With Steatotic Liver Disease and Liver Enzymes: A Multiplatform Population-Based Study","authors":"Yasir J. Abozaid ,&nbsp;Ibrahim Ayada ,&nbsp;Laurens A. van Kleef ,&nbsp;Neil J. Goulding ,&nbsp;Jessica S. Williams-Nguyen ,&nbsp;Robert C. Kaplan ,&nbsp;Robert J. de Knegt ,&nbsp;Lynne E. Wagenknecht ,&nbsp;Nicholette D. Palmer ,&nbsp;Nicholas J. Timpson ,&nbsp;Jill M. Norris ,&nbsp;Yii-Der Ida Chen ,&nbsp;M. Arfan Ikram ,&nbsp;Willem Pieter Brouwer ,&nbsp;Mohsen Ghanbari","doi":"10.1016/j.gastha.2024.09.006","DOIUrl":"10.1016/j.gastha.2024.09.006","url":null,"abstract":"<div><h3>Background and Aims</h3><div>Steatotic liver disease (SLD) is the most common chronic liver disease strongly associated with metabolic dysfunction, but its pathogenesis remains incompletely understood. Exploring plasma circulating metabolites may help in elucidating underlying mechanisms and identifying new biomarkers for SLD.</div></div><div><h3>Methods</h3><div>We examined cross-sectionally the association between plasma metabolites and SLD as well as liver enzymes using data from 4 population-based cohort studies (Rotterdam study, Avon Longitudinal Study of Parents and Children, The Insulin Resistance Atherosclerosis Family Study, and Study of Latinos). Metabolites were assessed in the Nightingale platform (n = 225 metabolites) by nuclear magnetic resonance spectroscopy and in the Metabolon platform (n = 991 metabolites) by ultra-high-performance liquid chromatography-mass spectrometry. Serum levels of liver enzymes (alanine aminotransferase, aspartate aminotransferase, and gamma-glutamyl transpeptidase) were measured and SLD was diagnosed by ultrasound or computed tomography scan. Logistic and linear regression models were performed per cohort and meta-analyzed. A false discovery rate &lt; 0.05 was considered as significant threshold.</div></div><div><h3>Results</h3><div>Several metabolites were significantly associated with SLD and liver enzymes, of which 21 metabolites were associated with both traits. The most significant associations were observed with phenylalanine, triglycerides in (high-density lipoprotein, intermediate-density lipoprotein, and small low-density lipoprotein), fatty acid (FA) ratios of (18:2 linoleic acid-to-total FA, omega 6 FA-to-total FA, and polyunsaturated FA-to-total FA) from the Nightingale and glutamate and sphingomyelin from the Metabolon platform. Other associated metabolites were mainly involved in lipid, amino acid, carbohydrates, and peptide metabolism.</div></div><div><h3>Conclusion</h3><div>Our study indicates a landscape of circulating metabolites associated with SLD. The identified metabolites may contribute to a better understanding of the metabolic pathways underlying SLD and hold promising for potential biomarkers in early diagnosis and monitoring of the disease.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 2","pages":"Article 100551"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11772964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Initial Diagnostic Strategies for Helicobacter Pylori in Patients With Bleeding Peptic Ulcers Undergoing Endoscopy: A Cost-Effectiveness Analysis","authors":"Michael G. Artin ,&nbsp;Josephine Soddano ,&nbsp;Sheila D. Rustgi ,&nbsp;Zainab Aziz ,&nbsp;Francesca Lim ,&nbsp;Jeong Yun Yang ,&nbsp;Myles A. Ingram ,&nbsp;John T. Nathanson ,&nbsp;John Y. Kao ,&nbsp;Chin Hur","doi":"10.1016/j.gastha.2024.100602","DOIUrl":"10.1016/j.gastha.2024.100602","url":null,"abstract":"<div><h3>Background and Aims</h3><div>Helicobacter pylori (H. pylori) is a major cause of peptic ulcer disease (PUD) and upper gastrointestinal bleeding. Testing for and eradication of H. pylori reduces the risk of future PUD-related complications including readmission for gastrointestinal bleeding. Our aim was to determine the most cost-effective testing strategy for H. pylori in patients hospitalized with bleeding peptic ulcers.</div></div><div><h3>Methods</h3><div>We developed a Markov cohort model to compare the following 6 H. pylori testing strategies: no testing, histology, rapid urease test, stool antigen test, urea breath test (UBT), and serology. Histology and rapid urease test require biopsies, while stool antigen test, UBT, and serology do not. We assumed a 17% H. pylori prevalence in patients admitted with bleeding ulcers. Model outcomes included hospitalizations for rebleeds, number needed to treat to avoid another hospitalization, life expectancy, total cost, quality-adjusted life years, and incremental cost-effectiveness ratios.</div></div><div><h3>Results</h3><div>Compared to no testing, UBT resulted in a gain of 0.02 quality-adjusted life years, total cost savings of $2140 per patient, and 1675 hospitalizations avoided per 10,000 patients per year. Additionally, the number needed to treat to avoid an additional hospitalization over 35 years was 167. UBT was the preferred strategy as it was both less costly and more effective than no testing.</div></div><div><h3>Conclusion</h3><div>Our findings suggest that UBT is the cost-effective strategy to identify H. pylori in patients admitted with PUD. Noninvasive H. pylori testing at the point of care or during inpatient admission should be considered, as it presents limited risk to patients and offers potential clinical benefits.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 4","pages":"Article 100602"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143237940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modeling Reductions in Liver Fat: Comparing Noninvasive Tests to Magnetic Resonance Imaging–Proton Density Fat Fraction","authors":"Santos Carvajal-Gonzalez ,&nbsp;Theresa Tuthill ,&nbsp;Vincent Wai-Sun Wong ,&nbsp;Amy Lauren Ashworth ,&nbsp;Zeid Kayali ,&nbsp;Céline Fournier-Poizat ,&nbsp;Neeta B. Amin","doi":"10.1016/j.gastha.2025.100669","DOIUrl":"10.1016/j.gastha.2025.100669","url":null,"abstract":"<div><h3>Background and Aims</h3><div>Magnetic resonance imaging–proton density fat fraction (MRI-PDFF) is an accurate, noninvasive tool for diagnosing metabolic dysfunction–associated steatotic liver disease, but its feasibility is limited in routine clinical practice. We aimed to assess the clinical utility of alternative, cost-efficient approaches for assessing liver fat changes and their relationship with MRI-PDFF changes.</div></div><div><h3>Methods</h3><div>This is a secondary analysis of a phase 2a study that included adults with metabolic dysfunction–associated steatotic liver disease who received clesacostat, a selective, reversible inhibitor of acetyl-CoA carboxylase. In this secondary analysis, responders were defined as those in whom a ≥30% decrease in liver fat by MRI-PDFF was observed with clesacostat or placebo. Other endpoints were evaluated for their ability to predict MRI-PDFF responder status, including controlled attenuation parameter (CAP), liver enzymes (alanine aminotransferase, aspartate aminotransferase, and gamma-glutamyl transferase), metabolic dysfunction–associated steatohepatitis–related biomarkers (liver stiffness measurement by vibration-controlled transient elastography, cytokeratin 18-M30, and cytokeratin 18-M65), and markers of hepatic steatosis (hepatic steatosis index and fatty liver index). These relationships were investigated through correlation, univariate, and multivariable regression analyses.</div></div><div><h3>Results</h3><div>Of 260 participants with a baseline and on-treatment measure at week 12 or week 16, 143 were responders. Based on correlation analyses, a significant but weak positive correlation between MRI-PDFF and CAP measurements of relative percentage change from baseline in liver fat was observed. By combining the selected 6 parameters (CAP, hepatic steatosis index, fatty liver index, alanine aminotransferase, gamma-glutamyl transferase, and cytokeratin 18-M65) through multivariable regression modeling, responders can be predicted with a high level of sensitivity and specificity (mean area under the receiver operating characteristic curve = 0.831 from 10-fold cross-validation).</div></div><div><h3>Conclusion</h3><div>Modeling multiple noninvasive assessments of liver fat closely aligned with MRI-PDFF measurements. These data support further assessment of its suitability in real-world clinical practice.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 7","pages":"Article 100669"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144071825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in Gastrointestinal Cancer Incidence in Asian American, Native Hawaiian, and Other Pacific Islander Groups","authors":"Vicki Tang ,&nbsp;Cynthia W. Ko","doi":"10.1016/j.gastha.2025.100653","DOIUrl":"10.1016/j.gastha.2025.100653","url":null,"abstract":"<div><h3>Background and Aims</h3><div>The Asian American, Native Hawaiian, and Other Pacific Islander (AANHPI) population are heterogeneous in health risk factors, socioeconomic status, and health outcomes. Disaggregating AANHPI groups may reveal disparities in cancer incidence. The aim of this study was to examine patterns and trends in incidence of common gastrointestinal cancers in AANHPI groups compared to the non-Hispanic White (NHW) population.</div></div><div><h3>Methods</h3><div>Using the detailed AANHPI Surveillance, Epidemiology, and End Results database, we retrospectively analyzed trends in incidence of colorectal adenocarcinoma (CRC), gastric adenocarcinoma (GC), hepatocellular carcinoma, pancreatic adenocarcinoma, and esophageal cancer from 1990 to 2014 using Surveillance, Epidemiology, and End Results∗Stat and Joinpoint software, compared to NHW. Additional analyses were stratified by age at diagnosis for CRC (&lt;50 and ≥50 years of age), for cardia and noncardia GC, and in esophageal cancer, for squamous cell carcinoma compared to esophageal adenocarcinoma.</div></div><div><h3>Results</h3><div>CRC incidence was comparable in Hawaiian, Japanese, and NHW groups, with differing trends in younger and older age groups. Hepatocellular carcinoma incidence was highest in Chinese and Southeast Asian groups, while GC incidence was high in Other Pacific Islander, Korean, and Japanese groups. There was less variability in pancreatic adenocarcinoma incidence between NHW and AANHPI groups. AANHPI groups had a higher incidence of esophageal squamous cell carcinoma but a lower incidence of esophageal adenocarcinoma compared to NHW.</div></div><div><h3>Conclusion</h3><div>Examining incidence of common gastrointestinal cancers in disaggregated AANHPI groups reveals differences in incidence rates and disparate trends over time. Further studies are needed to elucidate the reasons for these differing trends and to evaluate whether efforts to reduce cancer risk factors and promote appropriate cancer screening in high-risk AANHPI groups are needed to reduce cancer disparities.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 6","pages":"Article 100653"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143936783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in Acute Pancreatitis-Related Mortality Among US Adults from 1999 to 2020","authors":"Chun-Han Lo ,&nbsp;Rahul Pannala ,&nbsp;N. Jewel Samadder","doi":"10.1016/j.gastha.2025.100615","DOIUrl":"10.1016/j.gastha.2025.100615","url":null,"abstract":"","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 5","pages":"Article 100615"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143792367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pilot Study of Fecal Mitochondrial DNA in Inflammatory Bowel Disease Patients Demonstrates a High Sensitivity Assay With Likely Capacity to Differentiate Between Disease and Histologic Remission","authors":"Kevin Zhu ,&nbsp;Thomas Wallach ,&nbsp;Shagun Sharma ,&nbsp;Vivian Vega ,&nbsp;Meredith Pittman ,&nbsp;Joe Brown","doi":"10.1016/j.gastha.2025.100622","DOIUrl":"10.1016/j.gastha.2025.100622","url":null,"abstract":"","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 5","pages":"Article 100622"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143825600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enteropathic Arthritis Accompanied by Tuberculous Colitis: A Case Report","authors":"Agung Sandi Ramadan ,&nbsp;Cahyo Wibisono Nugroho","doi":"10.1016/j.gastha.2024.10.011","DOIUrl":"10.1016/j.gastha.2024.10.011","url":null,"abstract":"<div><div>Enteropathic arthritis (EnA) is a type of spondyloarthritis with inflammatory bowel disease, such as ulcerative colitis and Crohn’s disease, which is challenging to differentiate from tuberculous colitis. Patients with EnA living in endemic tuberculosis have a high risk of tuberculosis infection (tuberculous colitis), which triggers a recurrent increase in disease activity. Discontinuation of corticosteroid therapy in EnA and early start to antituberculosis drugs are recommended in the patients. Complete treatment of tuberculosis helps improve the prognosis of tuberculous colitis. Patient compliance in treatment plays a crucial role in managing tuberculous colitis exacerbated by EnA in endemic areas.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 3","pages":"Article 100571"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143420411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug-Induced Dysphagia and Diarrhea: A Case of Colchicine Toxicity","authors":"Meredith Yellen ,&nbsp;Rangesh Modi ,&nbsp;Rebecca Yao ,&nbsp;Tanner Storozuk ,&nbsp;Kevin Tanager ,&nbsp;Kg Reddy","doi":"10.1016/j.gastha.2025.100726","DOIUrl":"10.1016/j.gastha.2025.100726","url":null,"abstract":"<div><div>We report a 70-year-old woman with 1 year of progressive diarrhea, dysphagia, and 100-pound weight loss, resulting in severe protein–calorie malnutrition. Endoscopy revealed mid-esophageal webs, erosions, erythema, gastric antrum and duodenum congestion, and mucosal granularity in the sigmoid colon. Biopsies from the esophagus, duodenum, and colon showed ring mitoses, prominent dyskeratosis/apoptosis, epithelial atypia, and regenerative changes consistent with colchicine toxicity. Her symptoms resolved within 3 days of discontinuing colchicine.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 10","pages":"Article 100726"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144926408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}